Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study-Reference-Cited by-同舟云学术

Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study

Published:2024-06-19 Issue:7 Volume:14 Page:1875-1890
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Haselgruber Sofía,Fernández-Crehuet-Serrano Pablo,Fernández-Ballesteros María Dolores,Padial-Gómez Alicia,Hernández-Rodríguez Juan Carlos,Ortiz-Álvarez Juan,Navarro-Guillamón Pedro,Membrive-Jiménez Cristina,Cuenca-Barrales Carlos,Molina-Leyva Alejandro

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13555-024-01209-w.pdf

Reference24 articles.

1. Cosentyx | European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx. Accessed 10 Mar 2024.

2. Maronese CA, Moltrasio C, Genovese G, Marzano AV. Biologics for hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol. 2024;20(5):525–45.

3. Silverberg JI, Thyssen JP, Fahrbach K, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(9):1797–810.

4. Marzano AV, Genovese G, Casazza G, et al. Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133–40.

5. Melgosa Ramos FJ, García-Ruiz R, Mateu Puchades A, Martorell A. Can we improve prognosis in hidradenitis suppurativa? identifying patients in the window of opportunity. Actas Dermosifiliogr. 2024;115(2):213–4.